Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

26.89 -0.11 (-0.41%)

Streaming Delayed Price Updated: 12:50 PM EDT, Jul 24, 2026 Add to My Watchlist

Price and Volume

Volume	349,495
Open	27.03
Bid (Size)	26.86 (200)
Ask (Size)	26.93 (100)
Prev. Close	27.00
Today's Range	26.47 - 27.98
52wk Range	12.59 - 47.65
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date ↗

July 16, 2026

This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.

Via The Motley Fool

What to Know About This Mineralys Insider Sale Before a December FDA Date ↗

July 16, 2026

Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.

Via The Motley Fool

Performance

YTD	-24.7%	-24.7%
1 Month	+5.0%	+5.0%
3 Month	-5.6%	-5.6%
6 Month	-21.6%	-21.6%
1 Year	+102.0%	+102.0%

More News

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision ↗

June 23, 2026

Via The Motley Fool

Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance ↗

May 06, 2026

Via Chartmill

Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat ↗

March 12, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗

May 31, 2026

Via The Motley Fool

Mineralys (MLYS) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? ↗

April 07, 2026

Via The Motley Fool

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

Via The Motley Fool

Mineralys (MLYS) Q4 2025 Earnings Call Transcript ↗

March 12, 2026

Via The Motley Fool

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗

December 23, 2025

Via The Motley Fool

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗

November 27, 2025

Via The Motley Fool

MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗

November 10, 2025

Via Chartmill

Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗

November 07, 2025

Via Benzinga

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗

September 21, 2025

Via The Motley Fool

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗

September 16, 2025

Via The Motley Fool

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Via The Motley Fool

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 03, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

September 03, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Via Chartmill

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Frequently Asked Questions

Is Mineralys Therapeutics, Inc. - Common Stock publicly traded?

Yes, Mineralys Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Mineralys Therapeutics, Inc. - Common Stock trade on?

Mineralys Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mineralys Therapeutics, Inc. - Common Stock?

The ticker symbol for Mineralys Therapeutics, Inc. - Common Stock is MLYS on the Nasdaq Stock Market

What is the current price of Mineralys Therapeutics, Inc. - Common Stock?

The current price of Mineralys Therapeutics, Inc. - Common Stock is 26.89

When was Mineralys Therapeutics, Inc. - Common Stock last traded?

The last trade of Mineralys Therapeutics, Inc. - Common Stock was at 07/24/26 12:50 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.